Breast Cancer



  • ECOG E1Z11- A Cohort Study to Evaluate Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Women with Stage I-III Breast Cancer (Open for Asian, Native Hawaiian, and Pacific Islanders only)
  • ALLIANCE A011104– Study reviewing the effect of Preoperative Breast MRI on Surgical Outcomes, Costs, and Quality of Life of Women with Breast Cancer
  • WFU 98213– Preventing Antracycline Cardiovascular Toxicity with Statins (PREVENT)
  • Alliance A011401– A Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Stage Breast Cancer
  • Alliance A011502– A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: ABC Trial
  • NRG CC004- A Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • WF 97116– A Randomized Phase III Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment


  • NSABP B-51- A Phase III Randomized Clinical Trial Evaluating Standard or Comprehensive Radiation Therapy in Treating Patients with Early Stage Breast Cancer Previously Treated with Chemotherapy and Surgery


  • AFT-25– A Phase III Randomized Prospective Trial Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS

Triple Negative

  • ECOG EA1131- A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy.
  • NRG BR-003– A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positve or High Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • SWOG S1416– A Randomized Phase II Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
  • SWOG S1418/BR006– A Randomized Phase II Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 CM Residual Invasive Cancer or Positive Lymph Node after Neoadjuvant Chemotherapy

HER2 Negative BRCA Mutations

  • NSABP B-55– A Randomized Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

ER and/or PR Positive/HER2 Negative

  • SWOG S1207A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer
  • ECOG E2112– A Phase III Randomized Clinical Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor -Positive that is locally Advanced or Metastatic Breast Cancer
  • Alliance A011106– Alternate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study


Positive Sentinel Lymph Node

  • Alliance A011202– A Randomized Phase II Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

HER2 Positive

  • ACCRU RU011301I– A Phase II ATOP Trial: Adjuvant Ado-Trastuzumab Emtansine (T-DMI) for Older-Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer ( Temporarily Closed to Accrual)


  • NRG-BR002– A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer